Abivertinib Inhibits Megakaryocyte Differentiation and Platelet Biogenesis

Overview

Journal Front Med

Specialty General Medicine

Date 2021 Nov 18

PMID 34792736

Citations 9

Authors

Jiansong Huang

Xin Huang

Yang Li

Xia Li

Jinghan Wang

Fenglin Li

Xiao Yan

Huanping Wang

Yungui Wang

Xiangjie Lin

Jifang Tu

Daqiang He

Wenle Ye

Min Yang

Jie Jin

Affiliations

Soon will be listed here.

Abstract

Abivertinib, a third-generation tyrosine kinase inhibitor, is originally designed to target epidermal growth factor receptor (EGFR)-activating mutations. Previous studies have shown that abivertinib has promising antitumor activity and a well-tolerated safety profile in patients with non-small-cell lung cancer. However, abivertinib also exhibited high inhibitory activity against Bruton's tyrosine kinase and Janus kinase 3. Given that these kinases play some roles in the progression of megakaryopoiesis, we speculate that abivertinib can affect megakaryocyte (MK) differentiation and platelet biogenesis. We treated cord blood CD34 hematopoietic stem cells, Meg-01 cells, and C57BL/6 mice with abivertinib and observed megakaryopoiesis to determine the biological effect of abivertinib on MK differentiation and platelet biogenesis. Our in vitro results showed that abivertinib impaired the CFU-MK formation, proliferation of CD34 HSC-derived MK progenitor cells, and differentiation and functions of MKs and inhibited Meg-01-derived MK differentiation. These results suggested that megakaryopoiesis was inhibited by abivertinib. We also demonstrated in vivo that abivertinib decreased the number of MKs in bone marrow and platelet counts in mice, which suggested that thrombopoiesis was also inhibited. Thus, these preclinical data collectively suggested that abivertinib could inhibit MK differentiation and platelet biogenesis and might be an agent for thrombocythemia.

Citing Articles

Cluster analysis of sarcopenia in older adults: significant factors contributing to disease severity.

Machekhina L, Tkacheva O, Dudinskaya E, Shelley E, Mamchur A, Daniel V Eur Geriatr Med. 2025; 16(1):45-54.

PMID: 39808247 DOI: 10.1007/s41999-024-01153-0.

Association between the neutrophil-to-lymphocyte ratio and cancer in adults from NHANES 2005-2018: a cross-sectional study.

Li G, Zhang D, Li M, Yuan F, Hou X, He D Sci Rep. 2024; 14(1):23678.

PMID: 39390050 PMC: 11467198. DOI: 10.1038/s41598-024-75252-0.

Laser Therapy in Hypertrophic and Keloid Scars: A Systematic Review and Network Meta-analysis.

Foppiani J, Khaity A, Al-Dardery N, Hasan M, El-Samahy M, Lee D Aesthetic Plast Surg. 2024; 48(19):3988-4006.

PMID: 38760539 DOI: 10.1007/s00266-024-04027-9.

Critical shifts in lipid metabolism promote megakaryocyte differentiation and proplatelet formation.

de Jonckheere B, Kollotzek F, Munzer P, Gob V, Fischer M, Mott K Nat Cardiovasc Res. 2023; 2:835-852.

PMID: 38075556 PMC: 7615361. DOI: 10.1038/s44161-023-00325-8.

Advantage of ostarine over raloxifene and their combined treatments for muscle of estrogen-deficient rats.

Roch P, Noisser L, Boker K, Hoffmann D, Schilling A, Sehmisch S J Endocrinol Invest. 2023; 47(3):709-720.

PMID: 37672168 PMC: 10904410. DOI: 10.1007/s40618-023-02188-z.

References

Huang J, Li X, Shi X, Zhu M, Wang J, Huang S . Platelet integrin αIIbβ3: signal transduction, regulation, and its therapeutic targeting. J Hematol Oncol. 2019; 12(1):26. PMC: 6407232. DOI: 10.1186/s13045-019-0709-6. View

van der Meijden P, Heemskerk J . Platelet biology and functions: new concepts and clinical perspectives. Nat Rev Cardiol. 2018; 16(3):166-179. DOI: 10.1038/s41569-018-0110-0. View

Zhang W, Zha C, Lu X, Jia R, Gao F, Sun Q . Anti-βGPI/βGPI complexes induce platelet activation and promote thrombosis via p38MAPK: a pathway to targeted therapies. Front Med. 2019; 13(6):680-689. DOI: 10.1007/s11684-018-0673-5. View

Lefrancais E, Ortiz-Munoz G, Caudrillier A, Mallavia B, Liu F, Sayah D . The lung is a site of platelet biogenesis and a reservoir for haematopoietic progenitors. Nature. 2017; 544(7648):105-109. PMC: 5663284. DOI: 10.1038/nature21706. View

Espasandin Y, Glembotsky A, Grodzielski M, Lev P, Goette N, Molinas F . Anagrelide platelet-lowering effect is due to inhibition of both megakaryocyte maturation and proplatelet formation: insight into potential mechanisms. J Thromb Haemost. 2015; 13(4):631-42. DOI: 10.1111/jth.12850. View

Di Buduo C, Currao M, Pecci A, Kaplan D, Balduini C, Balduini A . Revealing eltrombopag's promotion of human megakaryopoiesis through AKT/ERK-dependent pathway activation. Haematologica. 2016; 101(12):1479-1488. PMC: 5479602. DOI: 10.3324/haematol.2016.146746. View

Wang J, Yi Z, Wang S, Li Z . The effect of decitabine on megakaryocyte maturation and platelet release. Thromb Haemost. 2011; 106(2):337-43. DOI: 10.1160/TH10-11-0744. View

Thiele J, Kvasnicka H, Schmitt-Graeff A . Effects of anagrelide on megakaryopoiesis and platelet production. Semin Thromb Hemost. 2006; 32(4 Pt 2):352-61. DOI: 10.1055/s-2006-942756. View

Xu X, Mao L, Xu W, Tang W, Zhang X, Xi B . AC0010, an Irreversible EGFR Inhibitor Selectively Targeting Mutated EGFR and Overcoming T790M-Induced Resistance in Animal Models and Lung Cancer Patients. Mol Cancer Ther. 2016; 15(11):2586-2597. DOI: 10.1158/1535-7163.MCT-16-0281. View

10.

Ma Y, Zheng X, Zhao H, Fang W, Zhang Y, Ge J . First-in-Human Phase I Study of AC0010, a Mutant-Selective EGFR Inhibitor in Non-Small Cell Lung Cancer: Safety, Efficacy, and Potential Mechanism of Resistance. J Thorac Oncol. 2018; 13(7):968-977. DOI: 10.1016/j.jtho.2018.03.025. View

11.

Benbarche S, Strassel C, Angenieux C, Mallo L, Freund M, Gachet C . Dual role of IL-21 in megakaryopoiesis and platelet homeostasis. Haematologica. 2017; 102(4):637-646. PMC: 5395104. DOI: 10.3324/haematol.2016.143958. View

12.

Yamashita Y, Miyazato A, Shimizu R, Komatsu N, Miura Y, Ozawa K . Tec protein-tyrosine kinase is involved in the thrombopoietin/c-Mpl signaling pathway. Exp Hematol. 1997; 25(3):211-6. View

13.

Avraham H, Price D . Regulation of megakaryocytopoiesis and platelet production by tyrosine kinases and tyrosine phosphatases. Methods. 1999; 17(3):250-64. DOI: 10.1006/meth.1998.0735. View

14.

Sangkhae V, Saur S, Kaushansky A, Kaushansky K, Hitchcock I . Phosphorylated c-Mpl tyrosine 591 regulates thrombopoietin-induced signaling. Exp Hematol. 2014; 42(6):477-86.e4. PMC: 5802363. DOI: 10.1016/j.exphem.2014.02.007. View

15.

Wang M, Blum K, Martin P, Goy A, Auer R, Kahl B . Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. Blood. 2015; 126(6):739-45. PMC: 4528064. DOI: 10.1182/blood-2015-03-635326. View

16.

Yan X, Zhou Y, Huang S, Li X, Yu M, Huang J . Promising efficacy of novel BTK inhibitor AC0010 in mantle cell lymphoma. J Cancer Res Clin Oncol. 2018; 144(4):697-706. DOI: 10.1007/s00432-017-2570-8. View

17.

Huang S, Yu M, Shi N, Zhou Y, Li F, Li X . Apigenin and Abivertinib, a novel BTK inhibitor synergize to inhibit diffuse large B-cell lymphoma . J Cancer. 2020; 11(8):2123-2132. PMC: 7052937. DOI: 10.7150/jca.34981. View

18.

Huang S, Li C, Zhang X, Pan J, Li F, Lv Y . Abivertinib synergistically strengthens the anti-leukemia activity of venetoclax in acute myeloid leukemia in a BTK-dependent manner. Mol Oncol. 2020; 14(10):2560-2573. PMC: 7530784. DOI: 10.1002/1878-0261.12742. View

19.

Huang S, Pan J, Jin J, Li C, Li X, Huang J . Abivertinib, a novel BTK inhibitor: Anti-Leukemia effects and synergistic efficacy with homoharringtonine in acute myeloid leukemia. Cancer Lett. 2019; 461:132-143. DOI: 10.1016/j.canlet.2019.07.008. View

20.

Ogura M, Morishima Y, Ohno R, Kato Y, Hirabayashi N, Nagura H . Establishment of a novel human megakaryoblastic leukemia cell line, MEG-01, with positive Philadelphia chromosome. Blood. 1985; 66(6):1384-92. View